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ABSTRACT
Invasive pneumococcal isolates from three hospi-
tals in Denver, CO, USA were serotyped between
1971 and 2004. Serotype 14 was most common
(13.2%), and other prevalent serotypes (3, 4, 6, 9
and 19) together accounted for 44.1% of the
isolates. All prevalent serotypes and 91.3% of the
total isolates were covered by pneumococcal
polysaccharide vaccine, while 79.1% of prevalent
serotypes and 56.7% of total isolates were covered
by pneumococcal conjugate vaccine. Serotypes 6,
9 and 14 were more common in the ﬁnal decade
than in the ﬁrst decade studied (37.3% vs. 20.2%),
whereas serotypes 3 and 23 were more common
in the ﬁrst decade (18.5% vs. 11.0%).
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Streptococcus pneumoniae causes >60 000 cases of
invasive disease (i.e., infections of normally sterile
sites) annually in the USA (http://www.cdc.gov/
ncidod/dbmd/abcs/survreports/spneu98.pdf),
with the highest rates occurring among young
children [1]. The 23-valent pneumococcal poly-
saccharide vaccines (PPV-23) licensed previously
cover 89% of the serotypes ⁄groups that cause
invasive disease in the USA [2], but fail to protect
children aged <2 years, and do not reduce
nasopharyngeal carriage, which is a source of
transmission [3].
In February 2000, a seven-valent pneumococcal
conjugate vaccine (PCV-7; Prevnar; Wyeth, Madi-
son, NJ, USA) was licensed in the USA for use
among infants and young children [1]. In June
2000, the Advisory Committee on Immunisation
Practices voted to include PCV-7 in the Vaccines
for Children programme [2]. PCV-7 has been
reported to prevent invasive pneumococcal dis-
ease in infants [4,5] and reduces nasopharyngeal
carriage [3,6,7]. It covers the most common
serotypes isolated from the blood or cerebrospinal
ﬂuid of children aged <6 years, but only 50% of
isolates from individuals aged ‡6 years in the
USA [8]. As the prevalence of pneumococcal
serotypes in a community may change with time
[8,9], periodic evaluation of the match between
serotypes causing invasive disease and those
serotypes covered by vaccines is important. The
present study determined serotype secular trends,
and the implications for vaccine efﬁcacy, in
Denver, CO, USA.
Between 1 January 1971 and 31 December 2004,
1490 invasive pneumococcal isolates from three
Denver hospitals (the Colorado General Hospital
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and the Denver Veterans Administration Hospital
in 1971–1980, and the Denver General Hospital in
1980–2004) were referred for serotyping, together
with data concerning the source of the isolate, the
age and gender of the patient, and the date of
isolation. Fresh subcultures of isolates were typed
using the Quellung reaction as described previ-
ously [10].
Serotype 14 was the most common serotype
(13.2%, 197 ⁄ 1490). Other prevalent serotypes (i.e.,
those with a prevalence rate of >5%) were
serotypes 3, 4, 6, 9 and 19, which together
accounted for 44.1% (657 ⁄ 1490). All prevalent
serotypes and 91.3% (1360 ⁄ 1490) of the total
isolates were represented in PPV-23. Although
coverage of PCV-7 was good for the prevalent
serotypes (79.1%, 520 ⁄ 657), only 56.7%
(845 ⁄ 1490) of the total isolates were covered by
PCV-7. The age of the patient was known for
55.4% (825 ⁄ 1490) of the isolates. Serotypes 14 and
3, respectively, were the most common serotypes
among patients aged £2 years (23.6%, 34 ⁄ 144)
and ‡65 years (18.6%, 21 ⁄ 113). Serotype coverage
provided by the PPV-23 and PCV-7 vaccines
for these two age groups is shown in Table 1.
Serotypes with ‡3% difference in prevalence rates
between the ﬁrst and last decades of the study are
shown in Table 2. Serotypes 6, 9 and 14 combined
were more prevalent in the ﬁnal decade (37.3%,
186 ⁄ 499 vs. 20.2%, 59 ⁄ 292). Serotypes 3 and 23
combined were more prevalent in the ﬁrst decade
(18.5%, 54 ⁄ 292 vs. 11.0%, 55 ⁄ 499). Coverage of
both vaccines was better in the ﬁnal decade
(93.2% vs. 89.0% for PPV-23; 61.1% vs. 50.7%
for PCV-7). An increase in invasive disease
caused by non-PCV-7 serotypes was noted during
2002 and 2003 (53.3%, 24 ⁄ 45 and 56.8%, 21 ⁄ 37,
respectively), but decreased during 2004 (36.7%,
11 ⁄ 30) to levels similar to those observed in 1999
before the introduction of PCV-7 (37.7%, 23 ⁄ 61).
A decrease in the number and proportion of
invasive isolates from children aged £2 years
compared with the total number of isolates
examined since the introduction of PCV-7 was
observed (6.8%, 14 ⁄ 207 in 2000–2004 vs. 21.0%,
130 ⁄ 618 in 1971–1999).
Strategies to limit antimicrobial resistance in
pneumococci involve improved surveillance,
rational use of antimicrobial agents and increased
vaccination of high-risk individuals. The current
23-valent polysaccharide vaccine covers 89% of
serotypes ⁄ groups causing invasive pneumococcal
disease in the USA [2], which is consistent with
the ﬁgure of 91.3% (1360 ⁄ 1490) of the total
isolates observed during the 34-year period of
the present study. Although 91.3% of the isolates
from patients aged £2 years were covered by
PPV-23, this vaccine is poorly immunogenic for
this age group [3]. In the present study, coverage
of PPV-23 for invasive isolates from patients aged
‡65 years was 87.6%, compared with a target of
90% [11]. PPV-23 is cost-effective for the preven-
tion of bacteraemic pneumococcal disease in the
elderly [12], but there are conﬂicting ﬁndings
concerning its efﬁcacy in preventing otitis media
in young children [13] and non-bacteraemic
pneumonia in the elderly [14].
In infants, PCV-7 elicits a T-cell-dependent
immunity with reliable anamnestic responses
[3]. Although PCV-7 contains fewer serotypes,
they account for 80% of invasive infections in
children aged £6 years, and 50% of infections in
those aged ‡6 years [8]. In the present study,
coverage of isolates from patients aged £2 years
and ‡65 years was 79.2% (114 ⁄ 144) and 43.4%
(49 ⁄ 113), respectively. Inclusion of additional
Table 1. Serotype coverage provided by pneumococcal
polysaccharide (PPV-23) and conjugate (PCV-7) vaccines
for patients aged £2 years (n = 144) and ‡65 years
(n = 112; one patient was infected with two different
serotypes) with invasive Streptococcus pneumoniae infec-
tions (Denver, CO, USA, 1971–2004)
Vaccine type
Age group
Isolates from patients aged
£2 years (n = 144)
Isolates from patients aged
‡65 years (n = 113)
PPV-23 96.5% (139 ⁄ 144) 87.6% (99 ⁄ 113)
PCV-7 79.2% (114 ⁄ 144) 43.4% (49 ⁄ 113)
Table 2. Invasive Streptococcus pneumoniae serotypes iso-
lated most frequently (isolates with a prevalence rate of
‡5%) during 1971–1980 (n = 292), 1981–1994 (n = 699) and
1995–2004 (n = 499) (Denver, CO, USA)
Years 1971–1980 Years 1981–1994 Years 1995–2004
Serotypea
No. of isolates
(% of total) Serotypea
No. of isolates
(% of total) Serotypea
No. of isolates
(% of total)
3 35 (12.0) 3 51 (7.3) 3 41 (8.2)
4 34 (11.6) 4 74 (10.6) 4 48 (9.6)
8 19 (6.5) 6 45 (6.4) 6 38 (7.6)
9 18 (6.2) 9 72 (10.3) 8 26 (5.2)
14 29 (9.9) 12 43 (6.2) 9 78 (15.6)
19 27 (9.3) 14 98 (14.0) 11 25 (5.0)
23 19 (6.5) 19 49 (7.0) 14
19
70 (14.0)
35 (7.0)
aOnly serotypes accounting for >5% of the total are listed.
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serotypes in the conjugate vaccine might lead to
poorer immunogenicity and more severe local
reactions [15]. There is a possibility of cross-
immunity among the serotypes included in the
vaccine and those serotypes not contained in the
vaccine, which may result in potentially greater
coverage and cross-protection [8,16].
By reducing nasopharyngeal carriage of vac-
cine serotypes, PCV-7 could promote herd immu-
nity, as is the case with Haemophilus inﬂuenzae b
(Hib) vaccine [3], and selectively reduce naso-
pharyngeal transmission of resistant strains [6,7].
Wider use of PCV-7 in young children could
prevent invasive disease in older individuals, for
whom exposure to children is a risk-factor [17].
Conversely, there is concern that any reduction in
nasopharyngeal carriage of PCV serotypes could
allow a selective increase in non-vaccine sero-
types [6,7], potentially leading to an increase in
invasive disease caused by non-vaccine sero-
types, as was observed during one clinical trial
[18]. Although an increase in invasive disease
caused by non-vaccine serotypes was observed
during 2002 and 2003, this dropped during 2004
to levels observed before the introduction of
PCV-7. Serotype coverage by both vaccines
improved unexpectedly between the ﬁrst and
last decades of the surveillance period (93.2% vs.
89.0% for PPV-23; 61.1% vs. 50.7% for PCV-7).
The present study, and those performed previ-
ously [8,9], documented shifts in serotype distri-
bution with time. Continuous or periodic
surveillance of invasive pneumococcal serotypes
is important to validate current vaccine compo-
sition and to guide the development of new
vaccines. More widespread use of pneumococcal
vaccines is needed to reduce the overall incidence
of pneumococcal disease.
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